Kelun-Biotech's Sac-TMT Hits Primary Endpoint in Phase III TNBC Trial
Event summary
- Kelun-Biotech's sac-TMT met primary endpoint of PFS in Phase III trial for first-line TNBC treatment.
- Interim analysis showed statistically significant and clinically meaningful improvement in PFS.
- Overall survival data is immature but shows a positive trend.
- Sac-TMT's safety profile consistent with previous studies, no new safety signals observed.
- Company plans to engage with CDE for regulatory pathway discussion.
The big picture
Kelun-Biotech's success in the Phase III trial positions sac-TMT as a potential first-line treatment for TNBC, expanding its market potential beyond later-stage indications. The positive results align with the company's strategy to address unmet needs in oncology, particularly in triple-negative breast cancer where treatment options are limited. The ongoing global trials with MSD further underscore the drug's potential to become a key player in the ADC space.
What we're watching
- Regulatory Pathway
- Whether CDE will expedite approval for sac-TMT in first-line TNBC treatment.
- Commercial Strategy
- How Kelun-Biotech will position sac-TMT against existing first-line TNBC therapies.
- Global Expansion
- The pace at which MSD advances global Phase III trials for sac-TMT.
Related topics